Dr. Felice C. Adler-Shohet, Pediatric Infectious Disease

Felice Adler, M.D., FAAP, has been working at CHOC since 2008 and is currently the director of outpatient services for the division of infectious diseases. She is board certified in pediatrics and pediatric infectious diseases. She received her medical degree from Vanderbilt University School of Medicine in Nashville, Tennessee. She completed her internship and residency training at the Vanderbilt University Children’s Hospital. Dr. Adler-Shohet completed her fellowship training in pediatric infectious diseases at Miller Children’s Hospital, Long Beach and University of California, Irvine College of Medicine. Dr. Adler has special interest in tuberculosis and neonatal infections.

Locations

CHOC Clinic
1201 W. La Veta Ave. Building: CHOC Clinic
Orange, CA 92868
phone: 888-770-2462
fax: 855-246-2329

Education

• Medical School
  Vanderbilt University School of Medicine, Nashville, TN
• Pediatric Infectious Diseases Fellowship
  Miller Children’s Hospital, Long Beach, CA
• Pediatric Residency
  Vanderbilt University Children’s Hospital, Nashville, TN

Academic Appointments

• Associate Clinical Professor, Pediatrics
  University of California, Irvine School of Medicine

Administrative Appointments

• Director, Infectious Diseases, Outpatient Services, CHOC
• Infectious Disease, CHOC Specialists

Editorial Boards

• Journal of Pediatrics
• Pediatric Infectious Diseases Journal
• Pediatrics

Professional Organizations

• American Academy of Pediatrics
• American Medical Association
• Infectious Diseases Society of America
• Pediatric Infectious Diseases Society

Publications

Le J, Adler-Shohet, FC. Time to Initiation of Antifungal Therapy for Neonatal Candidiasis. Antimicrob Agents and Chemother. 2013 June;57(6):2550-5

Okubo S, Cheung M, Adler-Shohet FC. Comparing indirect fluorecnet antibody assays to rapid diagnostic tests for the deletion of influenza A (H1N1)pmd09. MLO Med Lab Obs. 2012 Sep;44(9):8,10,12

Nutter S, Cheung M, Adler-Shohet F, Krusel K, Vogel K, Meyers H. Evaluation of Indirect Fluorescent Antibody Assays compared to Rapid Influenza Diagnostic Tests for the Detection of Pandemic Influenza A (H1N1 pdm09. . PloS ONE. 2012;7(3):e33097. Epub 2012 Mar 30.

Nieves D, Singh J, Ashouri N, Arrieta A, McGuire T, Adler-Shohet FC. Clinical and laboratory features of pediatric pertussis disease at the onset of a California epidemic. Pediatr. 2011 Dec;159(6):1044-6. Epub 2011 Sep 16

Green JS, Singh J, Cheung M, Adler-Shohet FC, Ashouri N. A cluster of pediatric endemic typhus cases in Orange County, California. Pediatr Infect Dis J. 2011 Feb; 30(2): 163-5.

Le J, San Agustin M, Hernandez EA, Tran TT, Adler-Shohet FC. Complications associated with outpatient parenteral antibiotic therapy in children. Clin Pediatr 2010; Nov;49(11):1038-43.

Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL; EPIC Study Group Participating Clinical Sites (Adler-Shohet FC). Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol. 2010 Sep;45(9):934-44.

Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity Associated with Amphotericin B Therapy in Neonates. Pediatr Infect Dis J. 2009 Dec;28(12):1061-3

Research Bio

Dr. Adler is very active in researching tuberculosis, bone and joint infections, and neonatal infections. She is currently evaluating possible causes of bone and joint infections in children. Dr. Adler is also well-researched in the area of neonatal infections and has several ongoing projects in this area.

Dr. Adler recently presented Management of Latent Tuberculosis Infections in Child Contacts of Multi-Drug Resistant Turberculosis, as a poster at the 48th Annual Meeting of the Infectious Diseases Society of America.

Our infectious disease specialists commonly treat:

• Infectious diseases, including those caused by multi-resistant bacteria
• Congenital and perinatal infections, including HIV
• Opportunistic infections in the immunocompromised patient
• Immunocompromised host
• Respiratory infections
• Viral and fungal infections
• Recurrent fever or fever of unknown origin
• Hepatitis A, B, C delta, E and G, as well as non-A – G
• Tuberculosis and Lyme disease
• Coccidiomycosis and other endemic fungal infections
• Travel medicine for children